| Today an ordinary shareholders’ meeting was conducted. The following resolutions were made: • Approval of the audited Annual Report for 2023 • Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022. • Approval of the Remuneration Report for 2023 • Approval of the remuneration of members of the Board of Directors • Re-election of Cornelis (Cees) de Jong as Chair and Jesper Brandgaard as Vice Chair of the Board of Directors • Re-election of Heine Dalsgaard, Sharon James, Kasim Kutay, Lise Kaae, Kevin Lane, Morten Sommer and Kim Stratton as members of the Board of Directors • Election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting • Approval to renew authorizations to the Board of Directors to implement capital increases • Approval to renew the authorization to the Board of Directors to acquire treasury shares • Approval of authorization to the Board of Directors to distribute extraordinary dividends • Approval of amendments to the Articles of Association • Approval of amendments to the Remuneration Policy Following the annual shareholders’ meeting, the Board of Directors consists of the following members: • Cornelis (Cees) de Jong, Chair • Jesper Brandgaard, Vice Chair • Heine Dalsgaard • Sharon James • Kasim Kutay • Lise Kaae • Kevin Lane • Morten Sommer • Kim Stratton Employee representatives: • Anne Breum • Anders Hentze Knudsen • Preben Nielsen • Jens Øbro • Karen Louise Lauesen, observer • Kim Ib Sørensen, observer For further information on members of the Board of Directors, please go to www.novonesis.com |
Attachment
